It’s Both the Vulnerable Patient and the Vulnerable Plaque

Slides:



Advertisements
Similar presentations
Ischaemic Heart Disease- Implications of Gender Dr Kaye Birks School of Rural Health Monash University Australia Gender Competency Training for Medical.
Advertisements

M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
Implications from PROSPECT and Future Directions Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Providing.
The Efficacy of Non-invasive Diagnostic for CAD in PMK Hospital Maj. Hutsaya Prasitdumrong, M.D. Cardiovascular Division, Department of Internal Medicine,
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
West Hertfordshire NHS Trust
Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010 FEDERICA.
Acute Coronary Syndrome. Acute Coronary Syndrome (ACS) Definition of ACS Signs and symptoms of ACS Gender and age related difference in ACS Pathophysiology.
DEFER STUDY: 5-YEAR FOLLOW-UP A Multicenter Randomized Study
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
HILLSBOROUGH COUNTY SHERIFF’S DEPARTMENT Saving Our Law Officers From Sudden Death and Heart Attacks.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
PLATFORM: Economic and Quality of Life Outcomes of an FFR CT Diagnostic Strategy in Suspected CAD Mark A Hlatky, Bernard De Bruyne, Gianluca Pontone, Manesh.
Ravi Doobay and Dr. Eric Harrison We care about the health of our firefighters Tampa Fire Rescue: Saving our Firefighters from Heart Disease.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
New strategies and perfusion/aspiration devices for primary PCI Sandra Garcia Cruset, PhD. Cordynamic B.U. Marketing Manager.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Simplifying Serial Lesion Assessment
LipiScan IVUS Coronary Imaging System
Total Occlusion Study of Canada (TOSCA-2) Trial
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
Lipid-Rich Plaque Study
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Disclosures Runlin Gao has received a research grant
The Prognostic Value of Coronary Artery Calcium in the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) Matthew J.
The American College of Cardiology Presented by Dr. Adnan Kastrati
Nightmares in the Cath Lab
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Atherosclerosis and HDL Therapy New Virtual Histology Findings
on behalf of the ABSORB II Investigators
Interesting Case Presentation
Novel atherectomy devices for the coronary calcified lesions
Intravascular Diagnostics: Do They Really Matter?
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Near-Infrared Spectroscopy: Lipid-Rich Plaque Study Update
Solved & Unsolved Issues
Clinical need for determination of vulnerable plaques
Near Infrared Spectroscopy: Case Studies and Clinical Relevance
The Tryton Bifurcation Trial:
On behalf of all principal COMPARE II investigators:
When IVUS? When FFR? Assessing Intermediate Lesions
BVS Expand: First Results of Wide Clinical Applications
FAVOR II Europe-Japan FAVOR II E-J
The American Heart Association Presented by Dr. Steven E. Nissen
OCT-Guided PCI What needs to be done to establish criteria?
On behalf of J. Belardi, M. Leon, L. Mauri,
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The American College of Cardiology Presented by Dr. Raimund Erbel
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
What oral antiplatelet therapy would you choose?
Gregg W. Stone, MD Columbia University Medical Center
CT coronary angiography and coronary calcium scoring
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Patient Examples of CMR Stress Test in Women Patient #1 is a 70-year-old, post-menopausal woman with typical angina and 3 coronary artery disease (CAD)
HILLSBOROUGH COUNTY SHERIFF’S DEPARTMENT
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
Train-the-Trainer Cases
(p for non-inferiority < 0.001)
Train-the-Trainer Cases
The American College of Cardiology Presented by Dr. A. Abazid
Train-the-Trainer Cases
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

It’s Both the Vulnerable Patient and the Vulnerable Plaque James Muller MD Brigham and Women’s Hospital CRT 19 February 2017

Disclosure Statement of Financial Interest No Disclosures

Cardiology Clinic Schedule Two Patients, Both Destined to Have a Coronary Event in the Next 2 Years 1:00 PM Joseph Smith MRN:43758417 Dx: Vulnerable Patient 1:20 PM Ellen Jones MRN:98249712 Dx: Vulnerable Patient due to Vulnerable Plaque

Vulnerable Patient Detection for Primary Prevention is Difficult

Is this a Vulnerable Patient? 60 year old female with atypical chest pain – April, 2008 Past Medical History: hypertension, obesity No family history of CAD No history of smoking Medications: metoprolol, nifedipine,triamterene Physical Exam: normal except for obesity Courtesy Dr. Ryan Madder, Beaumont Hospital

Coronary Artery Calcium Score = 0 April 2008 Coronary Artery Calcium Score = 0 Courtesy Dr. Ryan Madder, Beaumont Hospital

March, 2008 CT Angiogram Interpretation: No Significant Coronary Disease Courtesy Dr. Ryan Madder Beaumont Hospital

In March, 2009, 11 months after CTA Patient calls EMS due to sudden onset chest pain radiating to left arm. Courtesy Dr. Ryan Madder, Beaumont Hospital

Coronary Angiography Courtesy Dr. Ryan Madder, Beaumont Hospital

Courtesy Dr. Ryan Madder, Beaumont Hospital

Will it be Possible to Detect and Treat a Vulnerable Coronary Plaque and Prevent a Coronary Event? For Primary or Secondary Prevention? Courtesy Dr. Ryan Madder, Beaumont Hospital

Vulnerable Patient Detection for Secondary Prevention is Less Difficult – The Role of Invasive Imaging

Invasive NIRS Catheter Detection of Coronary Lipid-rich Plaques – Autopsy Comparison 40 mm 36 mm 20 mm 26 mm

Invasive Detection of LCBI in Non-culprit Artery Identifies Vulnerable Patients Above the Median Median LCBI = 43 Courtesy Drs. Rohit Oemrawsingh and Patrick Serruys, ESC, 2013

In the cohort of 70 post PCI patients, only 4 had maxLCBI4mm >600 Vulnerable Plaque? Unstable Angina at 7 months New culprit at vulnerable plaque site Stent placed in STEMI culprit In the cohort of 70 post PCI patients, only 4 had maxLCBI4mm >600 in non-stented area. Courtesy of Dr. Ryan Madder Spectrum Hospital Grand Rapids, MI Confidential

VP, 1989

Critics of Vulnerable Plaque Detection Efforts After 28 years of searching, the vulnerable plaque field is doomed – you are wasting your time and our money.

The Vulnerable Plaque Hype-pothesis Steve Nissen, MD, CRT Meeting, 2010 Requiem for the ‘vulnerable plaque’ Peter Libby and Gerard Pasterkamp, EHJ, March 2015 The Myth of the “Vulnerable Plaque” Transitioning From a Focus on Individual Lesions to Atherosclerotic Disease Burden for Coronary Artery Disease Risk Assessment Armin Arbab-Zadeh, MD, PHD,* Valentin Fuster, MD, PHD: JACC 2015

The Lipid-rich Plaque (LRP) Study Dr. Ron Waksman, PI PI, Europe, Dr The Lipid-rich Plaque (LRP) Study Dr. Ron Waksman, PI PI, Europe, Dr. Carlo Di Mario 2 year MACE from a new lesion at vulnerable patient and vulnerable plaque level 1,562 patients with ACS or SA underwent NIRS-IVUS imaging of 2 or more Vessels during PCI

LRP Study Vulnerable Plaque Endpoint Cause of Second Event Relationship between Max 4 mm LCBI and new culprit lesion in a given 30 mm segment of proximal, mid, or distal artery Max 4 mm LCBI 500 Suspected vulnerable plaque Cause of First Event Confidential 20

PROSPECT 2 Study PROSPECT / ABSORB RCT 900 ACS Patients Undergoing PCI Drs. Stone, Erlinge, Co-PIs Dr. Serruys, Chair, DSMB 900 ACS Patients Undergoing PCI “PROSPECT 2” 600 Patients “ABSORB” 300 pts > 70% Plaque Burden,Non-Flow -Limiting BVS Scaffold BVS Scaffold + GDMT 150 Patients GDMT Only 150 Patients NIRS/IVUS Predicts MACE LCP No LCP LCP No LCP Assess Treatment Effect in Sub-set with LCP

PROSPECT 2 – 900 Patients imaged and followed for events PIs –Dr. David Erlinge and Dr. Gregg Stone PROSPECT ABSORB -- 300 patients with PB>70% randomized to scaffold or standard care - Secondary endpoint - Safety and efficacy of BVS in lesions with large plaque burden which are LRP+ vs LRP-

Soon, the Data will Speak So when those results are available, you will no longer have to listen to Steve and me howling away -- Soon, the data will speak Soon, the Data will Speak